Adjuvant And Salvage Radiotherapy For Urothelial Cell Carcinoma Of Upper Urinary Tract: A Single Institute Experience

K. Fan,W. Leung,C. Chuang,M. Hsieh,Y. Lin,C. Liaw,J. Hong

DOI: https://doi.org/10.1016/j.ijrobp.2009.07.805

2009-01-01

Abstract:Urothelial cell carcinoma of upper urinary tract is relatively uncommon, and the role of radiotherapy is poorly defined. However, RT is still used postoperatively for some advanced disease or salvage of recurrence. This study was designed to investigate the results of radiotherapy (RT) for adjuvant or salvage treatment of upper urinary tract urothelial cell carcinoma (UTUC). Between July 1997 and Feburary 2007, 40 patients who had undergone curative radiotherapy after radical surgery were selected. Twenty patients received RT as adjuvant treatment (PORT). The indications of PORT were: positive resection margin, pathologic regional nodal metastasis, pathologic T4 disease, pathologic T3 with lymphovascular permeation or perineural invasion. The rest of them received RT as the salvage treatment (SART) for residual tumor after surgery or local-regional recurrence. The prescribed dose of RT ranged from 32 to 66.6 Gy (median: 50 Gy). Platinum-based chemotherapy was given to 34 patients in variable combination with RT regimens. Twenty-six patients received concurrent chemotherapy, 8 patients received chemotherapy and RT sequentially. The median follow-up time of living patients was 61 months (22 - 93 months). At the time of analysis, 10 patients were still alive, but 2 of them were alive with disease. Twenty-four patients died from disease recurrence, 2 and 2 patients died from complications and non-cancer comorbidities. One patient was lost to follow-up after tumor recurrence and one patient was lost to follow-up immediately after treatment completion. The 3-year overall survival was 45% and 16%, for PORT group and SART group, respectively (p = 0.03). The 3-year progression-free survival was 41% and 12%, for PORT group and SART group, respectively (p = 0.02). Tumor recurrence occurred in 29 patients. Distant metastasis was the most common first failure (17) followed by local-regional failure (12). Four patients also developed second primary urinary tract cancer during follow-up. Prescribed dose less than 50 Gy (p = 0.02) and SART (p = 0.04) were independent poor prognostic factors in multivariate analysis. In PORT group, the 3-year progression-free survival was improved from 16% to 56% if the prescribed dose was equal to or more than 50 Gy. In SART group, the 3-year progression-free survival was 34% if the prescribed dose was equal to or more than 50 Gy; and 0 if the prescribed dose was less than 50 Gy. RT should still be offered as a valid therapeutic option for advanced or recurrent UTUC. For better outcome, the prescribed dose should be no less than 50 Gy. Although long-term survival can be achieved even in SART group, the overall treatment result is poor. Investigation of novel effective treatment is needed.